Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
Neoadjuvant therapy for high-risk renal cell carcinoma (RCC) may offer a survival advantage over adjuvant therapy, according to data presented at ...
Dostarlimab achieved a 100% clinical complete response rate in patients with dMMR/MSI-H advanced rectal cancer, a phase 2 study found.
A final decision on marketing authorization is anticipated for Q1 of 2025.
The EMA’s CHMP has recommended the approval of belzutifan monotherapy for patients with select VHL disease–associated cancers.
ALLO-316, a CD70-targeting CAR T-cell therapy, has demonstrated activity in patients with previously treated, advanced ccRCC.
A study now reports that Cu, as a subunit of cytochrome c oxidase (CuCOX), promotes the development of clear cell renal cell carcinoma (ccRCC) through ...
“We did see that there was a certain percentage of individuals who had to have dose holding, and a smaller percentage of people had to have dose reduction, in general,” says Eric Jonasch, MD.
... (ccRCC) rather than non-ccRCC. The 5-year cancer-specific survival rate was 9.8% in patients with non-ccRCC and 20.7% in patients with ccRCC (P <.0001) ...
Partial nephrectomy showed similar overall and cancer-specific survival rates to radiofrequency ablation in patients with cT1a RCC.
Clear cell renal cell carcinoma (ccRCC) and ischemic stroke are critical global health challenges with a notable association. This study explores the correlation between tumor-related factors and ischemic stroke risk, aiming to construct a predictive nomogram model for ischemic stroke in ccRCC ...
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.